F-22Raptor
ELITE MEMBER
- Joined
- Jun 19, 2014
- Messages
- 16,980
- Reaction score
- 3
- Country
- Location
Stocks jumped Wednesday on the back of positive data from a potential coronavirus treatment from Gilead Sciences, while investors digested a sharp drop in U.S. economic activity.
The Dow Jones Industrial Average traded about 420 points, or 1.75%, higher. The S&P 500 gained 2% while the Nasdaq Composite traded roughly 2.7% higher.
A study of Gilead's remdesivir drug conducted by the National Institute of Allergy and Infectious Diseases met its primary endpoint, the drugmaker said, lifting expectations for a potential coronavirus treatment. Gilead also released the results of its own study, which showed improvement in patients taking remdesivir to treat the virus. Gilead shares jumped 3% after a brief halt in the premarket.
"The idea of something that is just given to you in the hospital IV that makes it so that it eliminates the, let's say, the odds of you dying is something that makes us feel like that maybe this is the Tamiflu for this dreaded disease," said CNBC's Jim Cramer. "I think a lot people are going to say open [the economy] up and that's why the market's flying."
Sentiment was also lifted as Alphabet shares gained 9.1% after the tech giant reported a revenue growth decline that was less steep than forecast. The company's YouTube ad revenues also beat expectations.
Other mega-cap tech stocks such as Facebook climbed 4.1%. Amazon gained 0.7% while Apple advanced 2.3%.
The Gilead news along with the strong move higher from Alphabet offset news of a steep drop in U.S. economic activity. U.S. GDP shrank by 4.8% in the first quarter for the country's biggest contraction since the financial crisis.
https://www.cnbc.com/2020/04/28/stock-market-futures-open-to-close-news.html
The Dow Jones Industrial Average traded about 420 points, or 1.75%, higher. The S&P 500 gained 2% while the Nasdaq Composite traded roughly 2.7% higher.
A study of Gilead's remdesivir drug conducted by the National Institute of Allergy and Infectious Diseases met its primary endpoint, the drugmaker said, lifting expectations for a potential coronavirus treatment. Gilead also released the results of its own study, which showed improvement in patients taking remdesivir to treat the virus. Gilead shares jumped 3% after a brief halt in the premarket.
"The idea of something that is just given to you in the hospital IV that makes it so that it eliminates the, let's say, the odds of you dying is something that makes us feel like that maybe this is the Tamiflu for this dreaded disease," said CNBC's Jim Cramer. "I think a lot people are going to say open [the economy] up and that's why the market's flying."
Sentiment was also lifted as Alphabet shares gained 9.1% after the tech giant reported a revenue growth decline that was less steep than forecast. The company's YouTube ad revenues also beat expectations.
Other mega-cap tech stocks such as Facebook climbed 4.1%. Amazon gained 0.7% while Apple advanced 2.3%.
The Gilead news along with the strong move higher from Alphabet offset news of a steep drop in U.S. economic activity. U.S. GDP shrank by 4.8% in the first quarter for the country's biggest contraction since the financial crisis.
https://www.cnbc.com/2020/04/28/stock-market-futures-open-to-close-news.html